LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been assigned an average rating of “Moderate Buy” from the six research firms that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $68.20.

Several equities research analysts have weighed in on the company. KeyCorp started coverage on LeMaitre Vascular in a report on Tuesday, February 6th. They issued a “sector weight” rating for the company. StockNews.com raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday, March 23rd. Finally, Barrington Research raised their price target on shares of LeMaitre Vascular from $66.00 to $69.00 and gave the stock an “outperform” rating in a report on Wednesday, February 28th.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, CFO Joseph P. Pellegrino, Jr. sold 36,967 shares of the stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $69.76, for a total transaction of $2,578,817.92. Following the sale, the chief financial officer now directly owns 6,452 shares of the company’s stock, valued at approximately $450,091.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other LeMaitre Vascular news, CFO Joseph P. Pellegrino, Jr. sold 36,967 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $69.76, for a total value of $2,578,817.92. Following the completion of the transaction, the chief financial officer now directly owns 6,452 shares of the company’s stock, valued at $450,091.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO George W. Lemaitre sold 36,600 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $68.03, for a total transaction of $2,489,898.00. Following the sale, the chief executive officer now directly owns 2,187,526 shares in the company, valued at approximately $148,817,393.78. The disclosure for this sale can be found here. Insiders have sold 114,036 shares of company stock worth $7,873,749 over the last 90 days. 12.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Comerica Bank acquired a new position in shares of LeMaitre Vascular during the 2nd quarter worth approximately $114,400,000. Mesirow Institutional Investment Management Inc. purchased a new stake in LeMaitre Vascular in the 4th quarter worth $8,837,000. Congress Asset Management Co. MA raised its position in LeMaitre Vascular by 36.3% during the third quarter. Congress Asset Management Co. MA now owns 508,379 shares of the medical instruments supplier’s stock worth $27,696,000 after acquiring an additional 135,266 shares during the period. Vanguard Group Inc. raised its position in LeMaitre Vascular by 10.1% during the first quarter. Vanguard Group Inc. now owns 1,426,235 shares of the medical instruments supplier’s stock worth $66,278,000 after acquiring an additional 130,881 shares during the period. Finally, Ranger Investment Management L.P. lifted its holdings in LeMaitre Vascular by 15.8% during the third quarter. Ranger Investment Management L.P. now owns 898,822 shares of the medical instruments supplier’s stock valued at $48,968,000 after purchasing an additional 122,601 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT opened at $67.20 on Friday. The stock has a market capitalization of $1.50 billion, a P/E ratio of 50.15, a P/E/G ratio of 2.82 and a beta of 0.88. The company’s 50-day simple moving average is $63.00 and its 200-day simple moving average is $56.82. LeMaitre Vascular has a fifty-two week low of $44.27 and a fifty-two week high of $74.64.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Tuesday, February 27th. The medical instruments supplier reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.02. LeMaitre Vascular had a net margin of 15.56% and a return on equity of 10.57%. The business had revenue of $48.90 million for the quarter, compared to analyst estimates of $49.01 million. During the same period in the previous year, the company earned $0.25 earnings per share. The business’s revenue for the quarter was up 19.3% on a year-over-year basis. On average, research analysts forecast that LeMaitre Vascular will post 1.66 EPS for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 28th. Stockholders of record on Thursday, March 14th will be issued a $0.16 dividend. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.14. This represents a $0.64 annualized dividend and a dividend yield of 0.95%. The ex-dividend date is Wednesday, March 13th. LeMaitre Vascular’s dividend payout ratio is 47.76%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.